Contrera JF[au] - Search Results

Year	Number of Results
1961	6
1962	4
1964	1
1965	1
1966	2
1967	2
1968	1
1972	1
1974	1
1975	1
1976	3
1977	1
1978	1
1980	1
1989	2
1990	2
1991	2
1993	1
1994	1
1996	1
1997	1
1998	3
1999	1
2000	1
2003	1
2004	3
2005	4
2006	5
2007	7
2008	4
2009	3
2010	1
2011	1
2013	2
2022	0

1

Foreword.

Contrera JF. Contrera JF. Toxicol Mech Methods. 2008;18(2-3):101. doi: 10.1080/15376510701860043. Toxicol Mech Methods. 2008. PMID: 20020907 No abstract available.

2

Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated products.

Kruhlak NL, Contrera JF, Benz RD, Matthews EJ. Kruhlak NL, et al. Among authors: contrera jf. Adv Drug Deliv Rev. 2007 Jan 10;59(1):43-55. doi: 10.1016/j.addr.2006.10.008. Epub 2006 Nov 15. Adv Drug Deliv Rev. 2007. PMID: 17229485 Review.

3

Genetic toxicity assessment: employing the best science for human safety evaluation. Part I: Early screening for potential human mutagens.

Jacobson-Kram D, Contrera JF. Jacobson-Kram D, et al. Among authors: contrera jf. Toxicol Sci. 2007 Mar;96(1):16-20. doi: 10.1093/toxsci/kfl191. Epub 2006 Dec 28. Toxicol Sci. 2007. PMID: 17194803 Review.

4

In vivo transgenic bioassays and assessment of the carcinogenic potential of pharmaceuticals.

Contrera JF, DeGeorge JJ. Contrera JF, et al. Environ Health Perspect. 1998 Feb;106 Suppl 1(Suppl 1):71-80. doi: 10.1289/ehp.98106s171. Environ Health Perspect. 1998. PMID: 9539006 Free PMC article. Review.

5

Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR models.

Contrera JF, Kruhlak NL, Matthews EJ, Benz RD. Contrera JF, et al. Regul Toxicol Pharmacol. 2007 Dec;49(3):172-82. doi: 10.1016/j.yrtph.2007.07.001. Epub 2007 Jul 17. Regul Toxicol Pharmacol. 2007. PMID: 17703860

6

The duration of non-rodent toxicity studies for pharmaceuticals. International Conference on Harmonication (ICH).

DeGeorge JJ, Meyers LL, Takahashi M, Contrera JF. DeGeorge JJ, et al. Among authors: contrera jf. Toxicol Sci. 1999 Jun;49(2):143-55. doi: 10.1093/toxsci/49.2.143. Toxicol Sci. 1999. PMID: 10416259 Review.

7

An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: II. Identification of genotoxicants, reprotoxicants, and carcinogens using in silico methods.

Matthews EJ, Kruhlak NL, Cimino MC, Benz RD, Contrera JF. Matthews EJ, et al. Among authors: contrera jf. Regul Toxicol Pharmacol. 2006 Mar;44(2):97-110. doi: 10.1016/j.yrtph.2005.10.004. Epub 2005 Dec 13. Regul Toxicol Pharmacol. 2006. PMID: 16352383

8

In Silico Screening of Chemicals for Genetic Toxicity Using MDL-QSAR, Nonparametric Discriminant Analysis, E-State, Connectivity, and Molecular Property Descriptors.

Contrera JF, Matthews EJ, Kruhlak NL, Benz RD. Contrera JF, et al. Toxicol Mech Methods. 2008;18(2-3):207-16. doi: 10.1080/15376510701857106. Toxicol Mech Methods. 2008. PMID: 20020915

9

In silico approaches to explore toxicity end points: issues and concerns for estimating human health effects.

Matthews EJ, Contrera JF. Matthews EJ, et al. Among authors: contrera jf. Expert Opin Drug Metab Toxicol. 2007 Feb;3(1):125-34. doi: 10.1517/17425255.3.1.125. Expert Opin Drug Metab Toxicol. 2007. PMID: 17269899 Review.

10

Inhibition of dopamine beta oxidase by adrenalone.

GOLDSTEIN M, CONTRERA JF. GOLDSTEIN M, et al. Among authors: contrera jf. Nature. 1961 Dec 16;192:1081. doi: 10.1038/1921081a0. Nature. 1961. PMID: 13899905 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results